IQVIA Holdings Inc. (IQV) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $235.62 (-0.93%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 8, 2026 | Elizabeth Anderson | Evercore ISI | $185.00 | -21.5% |
| Feb 6, 2026 | Luke Sergott | Barclays | $210.00 | -10.9% |
| Feb 5, 2026 | Elizabeth Anderson | Evercore ISI | $225.00 | -4.5% |
| Jan 8, 2026 | Dan Leonard | UBS | $280.00 | +18.8% |
| Jan 8, 2026 | Jailendra Singh | Truist Financial | $290.00 | +23.1% |
| Oct 29, 2025 | Dan Leonard | UBS | $250.00 | +6.1% |
| Oct 29, 2025 | Eric Coldwell | Robert W. Baird | $258.00 | +9.5% |
| Oct 2, 2025 | Luke Sergott | Barclays | $200.00 | -15.1% |
| Sep 3, 2025 | Jamie Clark | Redburn Partners | $214.00 | -9.2% |
| Jul 25, 2025 | Ann Hynes | Mizuho Securities | $225.00 | -4.5% |
| May 23, 2025 | Jamie Clark | Redburn Partners | $188.00 | -20.2% |
| May 15, 2025 | Ann Hynes | Mizuho Securities | $190.00 | -19.4% |
| May 7, 2025 | Luke Sergott | Barclays | $165.00 | -30.0% |
| Apr 25, 2025 | Sidharth Sahoo | HSBC | $160.00 | -32.1% |
| Nov 4, 2024 | Jaliendra Singh | Truist Financial | $265.00 | +12.5% |
| Oct 31, 2024 | Elizabeth Anderson | Evercore ISI | $235.00 | -0.3% |
| Oct 29, 2024 | Sean Dodge | RBC Capital | $270.00 | +14.6% |
| Oct 16, 2024 | Justin Bowers | Deutsche Bank | $270.00 | +14.6% |
| Oct 14, 2024 | Jamie Clark | Redburn Partners | $276.00 | +17.1% |
| Sep 20, 2024 | Eric Coldwell | Robert W. Baird | $256.00 | +8.7% |
Top Analysts Covering IQV
IQV vs Sector & Market
| Metric | IQV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.16 | 2.25 | 2.42 |
| Analyst Count | 19 | 8 | 19 |
| Target Upside | +9.1% | +16366.1% | +18.0% |
| P/E Ratio | 29.20 | 2.98 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $17.19B | $17.24B | $17.33B | 17 |
| 2027-12-31 | $17.82B | $18.23B | $18.74B | 17 |
| 2028-03-31 | $4.55B | $4.59B | $4.64B | 6 |
| 2028-06-30 | $4.69B | $4.73B | $4.78B | 5 |
| 2028-09-30 | $4.75B | $4.79B | $4.85B | 5 |
| 2028-12-31 | $5.02B | $5.07B | $5.12B | 6 |
| 2029-03-31 | $4.63B | $4.66B | $4.72B | 11 |
| 2029-06-30 | $4.76B | $4.80B | $4.86B | 10 |
| 2029-09-30 | $4.82B | $4.86B | $4.92B | 10 |
| 2029-12-31 | $4.97B | $5.01B | $5.07B | 11 |
| 2030-12-31 | $21.53B | $21.76B | $22.12B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $12.55 | $12.70 | $12.80 | 14 |
| 2027-12-31 | $13.60 | $14.08 | $14.80 | 14 |
| 2028-03-31 | $3.43 | $3.46 | $3.51 | 6 |
| 2028-06-30 | $3.69 | $3.73 | $3.79 | 6 |
| 2028-09-30 | $3.83 | $3.87 | $3.92 | 7 |
| 2028-12-31 | $4.44 | $4.49 | $4.55 | 9 |
| 2029-03-31 | $4.20 | $4.25 | $4.31 | 8 |
| 2029-06-30 | $4.42 | $4.47 | $4.54 | 8 |
| 2029-09-30 | $4.82 | $4.87 | $4.94 | 9 |
| 2029-12-31 | $5.21 | $5.27 | $5.35 | 11 |
| 2030-12-31 | $19.23 | $19.50 | $19.92 | 5 |
Frequently Asked Questions
What is the analyst consensus for IQV?
The consensus among 19 analysts covering IQVIA Holdings Inc. (IQV) is Buy with an average price target of $222.40.
What is the highest price target for IQV?
The highest price target for IQV is $320.00, set by Elizabeth Anderson CFA at Evercore ISI on 2021-11-19.
What is the lowest price target for IQV?
The lowest price target for IQV is $160.00, set by Sidharth Sahoo at HSBC on 2025-04-25.
How many analysts cover IQV?
19 analysts have issued ratings for IQVIA Holdings Inc. in the past 12 months.
Is IQV a buy or sell right now?
Based on 19 analyst ratings, IQV has a consensus rating of Buy (2.16/5) with a +9.1% upside to the consensus target of $222.40.
What are the earnings estimates for IQV?
Analysts estimate IQV will report EPS of $12.70 for the period ending 2026-12-31, with revenue estimated at $17.24B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.